1. [Primary breast diffuse large B-cell lymphoma-report of 21 cases from China with literatures review].
- Author
-
Sun X, Xu B, Li Y, Du J, Dong L, Gao X, Li G, Wei X, and Song Y
- Subjects
- Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms drug therapy, Breast Neoplasms pathology, China, Cisplatin, Cyclophosphamide, Dexamethasone, Doxorubicin, Etoposide, Female, Humans, Ifosfamide, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse pathology, Neoplasm Recurrence, Local, Prednisone, Prognosis, Retrospective Studies, Rituximab, Vincristine, Breast Neoplasms diagnosis, Lymphoma, Large B-Cell, Diffuse diagnosis
- Abstract
Objective: To evaluateclinical features, treatment and outcomes of patients diagnosed with primary breast diffuse large B-cell lymphoma(DLBCL)., Methods: Clinical data were analyzed for all patients diagnosed with primary breast DLBCL(n=21). Kaplan-Meier method was used to estimate 5- year overall survival(OS)rate, and the difference was compared by Log- rank test., Results: The 21 cases of patients with primary breast DLBCL were all female with median age at diagnosis as 48 years (range 21-64 years). 13 patients had International Prognostic Index(IPI)of 0, 6 IPI 1, and 2 IPI 2. The 5- year OS rates of CHOP/R- CHOP and R±DICE after R±EPOCH groups were 40.0% and 72.2% , respectively(P=0.035). The central nervous system relapse rate of CHOP/R-CHOP and R±DICE after R± EPOCH groups were 16.7% and 6.7%(P=0.500), respectively. The 5- year OS rates of patients with primary breast DLBCL staging Ⅱ E-Ⅲ E and Ⅰ E were 21.4% and 83.3% , respectively(P=0.025)., Conclusion: Primary breast DLBCL was rare. The patients of primary breast DLBCL with chemotherapy regimen of R±DICE after R±EPOCH might have a better prognosis and lower relapse rate of central nervous system; the primary breast DLBCL patients staging ⅡE-ⅢE might have a poor prognosis.
- Published
- 2015
- Full Text
- View/download PDF